Peptide-based drug design using generative AI
Chemical Communications · 2026 · 62 (3) · 672-691
DOI: 10.1039/d5cc04998a ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Communications, 2026. Verfasst von Srinivasan Ekambaram und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Virginia, Charlottesville, VA 22901, USA. dokh@virginia.edu. Hauptthemen laut MEDLINE: Peptides, Drug Design, Artificial Intelligence. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Advances in AI-driven peptide design are accelerating the discovery of peptide-based drugs with enhanced stability, specificity, and clinical potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Virginia, Charlottesville, VA 22901, USA. dokh@virginia.edu.
- Departments of Neuroscience, Pharmacology, Biomedical Engineering, Microbiology, Immunology, & Cancer Biology, University of Virginia, Charlottesville, VA 22901, USA.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Ekambaram, S., & Dokholyan, N. V. (2026). Peptide-based drug design using generative AI. Chemical Communications, 62(3), 672-691. https://doi.org/10.1039/d5cc04998a
Vancouver
Ekambaram S, Dokholyan NV. Peptide-based drug design using generative AI. Chemical Communications. 2026;62(3):672-691. doi:10.1039/d5cc04998a
BibTeX
@article{Ekambaram2026,
author = {Ekambaram, Srinivasan and Dokholyan, Nikolay V},
title = {Peptide-based drug design using generative AI},
journal = {Chemical Communications},
year = {2026},
volume = {62},
number = {3},
pages = {672--691},
doi = {10.1039/d5cc04998a}
}
EUVIMED